Tag: Admedus

CardioCel use improves management of critically ill neonates

 Tomasz Mroczek (Kraków, Poland) talks to Cardiovascular News at ECHSA 2019 (European Congenital Heart Surgeons Association, 20 – 22 June, Sofia, Bulgaria) – where...

ECHSA 2019: CardioCel acellular bioscaffold handles well

Caner Salih (London, UK) talks to Cardiovascular News about the CardioCel bioscaffold (Admedus) and the benefits it has brought to his practice at Guy's...

Admedus’ announces favourable five-year outcomes for its CardioCel bioscaffold

Admedus has announced positive data from an independent study into the performance of its tissue engineered bovine pericardial implant CardioCel, which is used in...

CardioCel 3D and VascuCel receive regulatory approval in Europe

Admedus has received the CE mark for its CardioCel 3D product portfolio and its next-generation collagen bioscaffold VascuCel in Europe. According to a press...

CardioCel now approved for use in the UAE

Admedus has announced that, in collaboration with its regional partner Genpharm, it has received market approval for CardioCel in the United Arab Emirates (UAE)...

Long-term study indicates no calcification with CardioCel after eight years

Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel (Admedus) shows that all patients...